Table 1. Randomized Studies Comparing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy in First-Line Treatment of Non-Small-Cell Lung Cancer
StudyTKIEGFR mutations (n)ORR (TKI vs CT) (%)Median PFS (TKI vs CT) (months)OS (TKI vs CT) (months/HR)
First-SignalGefitinib2784 vs 378.4 vs 6.730.6 vs 26.5
IPASSGefitinib13271 vs 479.8 vs 6.421.6 vs 21.9
NEJGSG002Gefitinib22874 vs 2910.8 vs 5.427.7 vs 26.6
WJTOG3405Gefitinib17262 vs 329.2 vs 6.3NA
OPTIMALErlotinib15483 vs 3613.7 vs 4.6NA
EURTACCErlotinib17358 vs 159.7 vs 5.2NA
Lux-Lung 3Afatinib30856 vs 2313.6 vs 6.9HR: 1.12
Lux-Lung 6Afatinib36467 vs 2311 vs 5.6HR: 0.95
  • CT, chemotherapy; EGFR, epidermal growth factor receptor; HR, hazard ratio; NA, not available; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.